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Abstract 
Background: Discogenic low back pain is one of the leading causes of pain and disability across the world.  A 
growing interest in the area of regenerative medicine, led by an improved understanding of the role of 
mesenchymal stem cells in tissue homeostasis and repair.  
Cases Report: We had two patients suffered from chronic discogenic low back pain. They were underwent 
injection of intra-discal 1.5 cc of Adipose Derived Mesenchymal Stem Cells (ADMSC) and followed up for 6 
months. After this period of time, there was a significant reduction in both VAS and ODI scores in patients.  
Conclusion: These data warrant further studies so that we can enhance our understanding of the other unknown 
mechanisms, which may exist behind stem cell injection. If the effectiveness of such injection to reduce pain and 
improve function is shown in the upcoming studies, it may provide a new insight for increasing this method of 
treatment as a proper option in the near future. 
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Low back pain (LBP) is one of the leading causes of 
disability and has enormous social and economic 
impact of patients and their family members1,2. 
Approximately 80% of adults experience LBP at some 
point in their lifetime, with a prevalence ranging from 
15 to 45%, and the prevalence of chronic LBP 
increases with age due to global population aging, 
changes in lifestyle, and occupational stresses2-4. 
Intervertebral disc (IVD) degeneration is 
characterized by progressive and irreversible IVD 
degradation due to many different causes2-4. The causes 
of this degeneration are complex and multifactorial, and 
include genetic, nutritional, and mechanical 
influences2,5. Intervertebral disc degeneration is 
characterized by progressive decline in nucleus 
pulposus (NP) hydration due to the loss of extracellular 
matrix (ECM) molecules such as aggrecan and 
collagen2,5. This dehydration of disc could lead to a loss 
of mechanical tension in the collagen fibers of the 
annulus fibrosis and result in abnormal spinal axial 
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loading forces and segmental instability6. Eventually, 
IVD degeneration can result in abnormalities of other 
parts of the IVD such as endplate and facet joint and 
develop into serious conditions, or facet joint 
syndrome7,8. 
The surgical procedures to correct herniated disc or 
spinal stenosis caused by IVD degeneration do not 
address the abnormal increase in pro-inflammatory 
cytokine levels of the degenerated disc or the inherent 
loss of functional native cells within the IVD. Our 
research is focusing on the development of stem cell-
based therapies to inhibit aberrant cytokine 
production, stimulate matrix anabolism production, 
and repopulate and influence the native cells. IRB 
approval was obtained from Shahid Beheshti 
University of Medical Sciences 
(IR.SBMU.REC.1397.045 ). 
Several adult stem cell types have been applied in 
preclinical and clinical studies2, 9-11, and mesenchymal 
stem cells (MSCs) have been anticipated as an ideal 
cell source for IVD regeneration because of their 
immune-modulatory functions and capacity for 
cartilage differentiation. Few studies as a human 
clinical trial demonstrated improved pain and 
disability scores as well as increased water content in 
the disc 12 month after MSC implantation9-11. MSCs 
implantation in degenerated IVD may induce 
osteophyte formation by cell leakage. 
Case Report 
Case 1: A 40 year old female complained of lumbar 
back pain for 10 years, she had not any history of 
disease except for hypothyroidism, which was under 
control, and the lab tests were within normal limit. 
According to the MRI, the disc of L5-S1 was 
involved. Preoperative VAS score and ODI score were 
8 and 32, respectively. The preoperative Pfirrmann 
score was assessed grade IV for this patient. After 
injection of 12×10⁶  ADMSC in 1.5 ml, the ODI score 
was measured at 1 week (wk), 1, 3 and 6 months after 
injection. This score was 32 at 1 wk, 28 at 1, 3 and 6 
months after injection. The VAS score at 1 wk was the 
same as pre-operation score. At 1 month and 3 months 
after injection, 70% reduction in VAS pain score was 
seen. At 6 months after injection, this reduction 
reached 80% improvement compare to pre-operation.  
Case 2: A 37 year old male complained of lumbar 
back pain with no history of any disease and the lab tests 
were within normal limit. Preoperative VAS, and ODI 
scores was 7, and 28, respectively. The preoperative 
Pfirrmann score was also assessed grade IV for this 
patient. After injection of 107 cells ADMSC in 1.5 ml, 
the ODI score was measured at 1 wk, 1, 3 and 6 months 
after injection. This score was 30 at 1 wk, 20 at 1, 3 and 
6 months after injection. The VAS score at 1 wk was 
the same as pre-operation score, At 1 month and 3 
months after injection 40% reduction in VAS score was 
seen. At 6 months after injection, this reduction reached 
70% improvement compared to pre-operation. 
Discussion 
MSC-based intradiscal treatment has recently attracted 
attention for its potential to revolutionize the treatment 
of chronic discogenic LBP by repopulating the IVD and 
restoring functional tissue through matrix synthesis by 
implanted cells and possible beneficial effects on native 
cells4. At least four published studies have used MSC-
based therapies to treat chronic discogenic LBP9,10,12. 
Yoshikawa et al10 first reported significant LBP 
reduction and rehydration of the treated disc following 
percutaneous injection of autologous BM-MSCs within 
a collagen sponge in two older patients with markedly 
degenerated disc. Orozco et al9 reported pilot study of 
10 patient with chronic discogenic LBP treated with 
percutaneous intradiscal injection of autologous BM-
MSCs, in which 90% of patient reported clinical 
benefit, and both LBP and disability were greatly 
reduced at 3 months after transplantation, followed by 
modest additional improvement at 6 and 12 months. 
MRI also showed marginally improved hydration of the 
treated disc at 12 months6-9. Pettine et al12 evaluated the 
use of autologous, concentrated BM cells considered to 
contain multiple stem and progenitor cells, including 
MSCs, and demonstrated significant improvement in 
the VAS, ODI, and modifier Pfirrmann score at 3, 6 and 
12 months post transplantation. In their study, patients 
who received more than 200 colony-forming unit-
fibroblasts (CFU-F) per milliliter of bone marrow 
aspirate showed significantly greater improvement of 
discogenic LBP compared to the others.  
In another study conducted by Kumar et al13 it was 
revealed that combined adipose tissue-derived 
mesenchymal stem cells (AT-MSC) and hyaluronic 
acid derivative in chronic discogenic LBP is safe and 
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tolerable and among six patients who achieved 
significant improvement in VAS, and ODI three 
patients determined to have increased apparent 
diffusion coefficient on diffusion MRI.  
However, we assume that injection of MSCs into the 
degenerated disc improves ECM production by 
degenerated host NP cells, increases NP-like gene 
expression, and modulates the immunological 
response of NP cells to inflammatory cytokines. The 
immune-modulatory effects of MSCs on NP cells 
within the degenerated disc could potentially inhibit 
the inflammatory cascade, thereby preventing 
ingrowth of pain-inducing vasculature and nerve 
fibers2,8,12-17. 
Conclusion 
These data warrant further studies so that we can 
enhance our understanding of the other unknown 
mechanisms, which may exist behind stem cell 
injection. If the effectiveness of such injection to 
reduce pain and improve function is shown in the 
upcoming studies, it may provide a new insight for 
increasing this method of treatment as a proper option 
in the near future. 
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